University Duke UniversityA real-world study provides new insights into the safety of a new Alzheimer’s disease drug. Key findings for this group:People with a specific high‑risk Alzheimer’s gene (APOE ε4 homozygotes) were about four times more likely to develop ARIA. “Our study highlights the urgent need to develop better tests to predict who will develop serious ARIA and to know when it is safe to resume treatment.” “The decision of whether or not these new medications are right for you is highly individualized,” says Heather Whitson, coauthor of the study and codirector of the Duke & UNC Alzheimer’s Disease Research Center. Sally Osmer didn’t hesitate when her doctors at Duke Health offered lecanemab as a treatment after she was diagnosed with early-stage Alzheimer’s disease at age 74.